Entera Bio (ENTX) Enterprise Value (2017 - 2026)
Entera Bio's (ENTX) quarterly Enterprise Value came in at -$4.1 million in Q1 2026, up 67.1% YoY from -$2.5 million in Q1 2025, and up 72.2% on a QoQ basis from -$14.9 million in Q4 2025.
Entera Bio (ENTX) Enterprise Value (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 10 years of Enterprise Value data on file, last reported at -$4.1 million in Q1 2026.
- Quarterly Enterprise Value rose 67.1% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.1 million (up 67.1% YoY) and the FY2025 annual result came in at -$14.9 million, down 71.86% from the prior year.
- Enterprise Value grew to -$4.1 million in Q1 2026, from -$14.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$4.1 million in Q1 2026 to a low of -$20.1 million in Q1 2022.
- A 5-year average of -$11.0 million and a median of -$10.7 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2025 — Enterprise Value tumbled 71.86% — and 2026, when it surged 67.1%.
- Tracing ENTX's Enterprise Value over 5 years: stood at -$12.3 million in 2022, then grew by 10.48% to -$11.0 million in 2023, then increased by 21.41% to -$8.7 million in 2024, then plunged by 71.86% to -$14.9 million in 2025, then jumped by 72.2% to -$4.1 million in 2026.
- The last three Enterprise Value figures came in at -$4.1 million (Q1 2026), -$14.9 million (Q4 2025), and -$8.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | -11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.31 Mn |
| Mar 31, 2026 | -4.14 Mn |
| Dec 31, 2025 | -14.88 Mn |
| Sep 30, 2025 | -8.57 Mn |
| Jun 30, 2025 | -10.86 Mn |
| Mar 31, 2025 | -12.57 Mn |
| Dec 31, 2024 | -8.66 Mn |
| Sep 30, 2024 | -6.92 Mn |
| Jun 30, 2024 | -9.06 Mn |
| Mar 31, 2024 | -9.19 Mn |
| Dec 31, 2023 | -11.02 Mn |
| Sep 30, 2023 | -7.59 Mn |
| Jun 30, 2023 | -9.14 Mn |
| Mar 31, 2023 | -10.69 Mn |
| Dec 31, 2022 | -12.31 Mn |
| Sep 30, 2022 | -14.32 Mn |
| Jun 30, 2022 | -17.28 Mn |
| Mar 31, 2022 | -20.11 Mn |
| Dec 31, 2021 | -24.89 Mn |
| Sep 30, 2021 | -27.40 Mn |